VP of Business Development at Poolbeg Pharma, David English, gives an overview of his experience and why he decided to join the Poolbeg Pharma team.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
HOOKIPA Pharma is advancing HIV treatment with its Phase 1b trial for HB-500. This innovative therapy aims to boost immune responses in individuals with HIV.
The pharmaceutical industry is being revolutionised by AI, transforming drug discovery with faster research and innovative treatments. Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, leveraging a novel clinical model for faster product development.
HOOKIPA Pharma Inc. and Poolbeg Pharma plc are in discussions for a potential acquisition to create a leading biopharmaceutical company focused on innovative medicines.
Discover how groundbreaking research is revolutionising disease treatment at Monash Institute of Pharmaceutical Sciences. AI, biology, and data converge for life-changing advancements.
Poolbeg Pharma, led by Cathal Friel, is on the brink of a transformative merger with Hookipa Pharma, backed by Gilead Sciences. Exciting times ahead!
Gilead Sciences shows strong support for potential merger between Poolbeg Pharma and Hookipa, signaling a transformative shift in biopharma landscape.
US-based biopharmaceutical innovator Hookipa Pharma is advancing non-binding discussions to acquire London-based Poolbeg Pharma in an all-share deal. This transformative proposal could reshape the clinical-stage biopharmaceutical landscape, creating a Nasdaq-listed powerhouse focused on next-generation immunotherapies for
Poolbeg Pharma, led by Cathal Friel, explores merger with Hookipa for Nasdaq listing. A potential game-changer in biopharmaceutical sector.
Poolbeg Pharma’s new treatment, POLB 001, shows promise in reducing cytokine release syndrome, a common side effect of cancer immunotherapies. Learn more here.
Poolbeg Pharma presents promising data for POLB 001 at ASH Annual Meeting, showing potential in cancer immunotherapy-induced CRS. Learn more here.
Discover how Dundalk Institute of Technology’s WISDOM mentorship initiative is shaping the careers of science students, bridging academia with industry experience.
Poolbeg Pharma plc (LON: POLB), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced key insights from its poster presentation at the 66th American
Discover how artificial intelligence is transforming drug development by streamlining data processing and enhancing predictive models for more efficient research.
The 66th ASH Annual Meeting and Exposition will be held from 7–10 December 2024, in San Diego, California, with an online component. As the most extensive event in the field of hematology, this gathering offers unparalleled
Poolbeg Pharma plc, a clinical-stage biopharmaceutical company, has announced that the US Patent Office will grant its US Immunomodulator I patent application. The patent covers POLB 001, a selective p38 MAP kinase inhibitor, and other similar
Poolbeg Pharma plc (LON:POLB), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the US Patent Office has notified the Company of its official decision
Artificial intelligence in the pharmaceutical industry has become central to modern drug discovery and development. Recognising both its potential and its risks, the FDA has initiated efforts to regulate AI’s role in the sector, balancing innovation
Poolbeg Pharma plc (LON:POLB), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that it will present a poster detailing POLB 001’s efficacy in reducing
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.